Crinetics Pharmaceuticals (CRNX) Total Liabilities (2017 - 2026)

Crinetics Pharmaceuticals' Total Liabilities history runs 10 years deep, the most recent figure standing at $120.7 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 12.44% year-over-year to $120.7 million in Q1 2026; TTM through Mar 2026 was $120.7 million, a 12.44% increase from a year earlier, with the FY2025 full-year figure at $134.2 million, up 22.21% from the prior year.
• Total Liabilities eased to $120.7 million in Q1 2026 per CRNX's latest filing, from $134.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $134.2 million in Q4 2025 and bottomed at $30.2 million in Q1 2022.
• The 5-year median for Total Liabilities is $103.2 million (2024), against an average of $83.8 million.
• Across the five-year window, Total Liabilities jumped 206.48% in 2024 and rose 3.98% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $35.8 million in 2022, then soared by 168.49% to $96.2 million in 2023, then grew by 14.07% to $109.8 million in 2024, then advanced by 22.21% to $134.2 million in 2025, then dropped by 10.06% to $120.7 million in 2026.
• Per Business Quant, the three latest CRNX Total Liabilities figures stand at $120.7 million (Q1 2026), $134.2 million (Q4 2025), and $123.9 million (Q3 2025).